Bionomics shares are trading higher after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.
Portfolio Pulse from Benzinga Newsdesk
Bionomics announced that its ATTUNE trial met its primary endpoint, showing that BNC210 treatment led to a significant reduction in total PTSD symptom severity at 12 weeks. This positive news has led to an increase in Bionomics' share price.
September 28, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bionomics' shares are trading higher after positive results from the ATTUNE trial. The successful BNC210 treatment could potentially boost the company's market position and revenue in the future.
The successful results from the ATTUNE trial indicate that Bionomics' BNC210 treatment is effective in reducing PTSD symptoms. This could potentially lead to increased demand for the treatment, boosting the company's revenue and positively impacting its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100